Evidence map›Paper›PMID 19699284›Full record

ArticleInternational journal of pharmaceutics2009

Preformulation, formulation, and in vivo efficacy of topically applied apomine.

Philip J Kuehl, Steven P Stratton, Marianne B Powell, Paul B Myrdal

Open access · greenAbstract read
In one paragraph

Article in International journal of pharmaceutics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Philip J KuehlLovelace Respiratory Research Institute, 2425 Ridgecrest Drive SE, Albuquerque, NM 87108, United States. pkuehl@lrri.org
Steven P Stratton
Marianne B Powell
Paul B Myrdal
University of Arizona · USLovelace Respiratory Research Institute · USStanford University · US

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Justin M Snider · 1985 to 2026
$110.2M
SOUTHWEST ENVIRONMENTAL HEALTH SCIENCES CENTERP30ES006694 · NIEHS · UNIVERSITY OF ARIZONA · PI Paloma Inés Beamer · 1994 to 2026
$36.7M
VITAMIN A, AND ITS PRECURSORS AND DERIVATIVES AS THERAPEUTIC MODALITIESP01CA027502 · NCI · UNIVERSITY OF ARIZONA · PI BOWDEN, TIMOTHY · 1985 to 2015
$36.3M
NCI NIH HHS CA023074NCI NIH HHS CA27502NCI NIH HHS P01 CA027502NCI NIH HHS P30 CA023074NIEHS NIH HHS ES06694NIEHS NIH HHS P30 ES006694
6 · The paper itself

Abstract

Apomine is a novel compound that inhibits the mevalonate/isoprenoid pathway of cholesterol synthesis and may prove effective as a skin cancer chemoprevention therapy. This research was focused on the development of a new delivery approach for chemoprevention of melanoma using topically delivered apomine. This included evaluating the effect of several factors on the stability of apomine in solution, utilizing these to develop a topical formulation, and conducting efficacy studies with the developed topical formulation in the TPras mouse model. Preformulation included the influence of pH, buffer species, ionic strength, and organic solvents on the stability of apomine at four different temperatures. Apomine was determined to undergo apparent first-order degradation kinetics for all conditions evaluated. Apomine undergoes base-catalyzed degradation. Less than 15% degradation is observed after >200 days under acidic conditions. Long-term stability studies were performed on two different topical cream formulations and indicate that both formulations are chemically stable for over 1 year at both 4 and 23 degrees C. The efficacy of topically applied apomine, from ethanol and developed 1% cream, was evaluated in vivo against the incidence of melanoma. Regardless of delivery vehicle apomine treatment caused a significant reduction in tumor incidence. Ethyl alcohol application of apomine resulted in a greater tumor incidence reduction when compared to the development cream formulation; however, this difference was not significant.

Indexed as

9,10-Dimethyl-1,2-benzanthraceneAdministration, TopicalAnimalsAnticarcinogenic AgentsBuffersChemistry, PharmaceuticalChromatography, High Pressure LiquidDiphosphonatesDrug StabilityEthanolHydrogen-Ion ConcentrationKineticsMelanoma, ExperimentalMiceOintmentsOsmolar Concentration9,10-Dimethyl-1,2-benzanthraceneAnticarcinogenic AgentsapomineBuffersDiphosphonatesEthanolOintmentsras ProteinsSolvents

Identifiers

PMID19699284
PMCPMC2783960
OpenAlexW2085845703

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.